Currently out of the existing stock ratings of Matthew Caufield, 107 are a BUY (85.6%), 18 are a HOLD (14.4%).

Matthew Caufield

Work Performance Price Targets & Ratings Chart

Analyst Matthew Caufield, carries an average stock price target met ratio of 27.25% that have a potential upside of 27.08% achieved within 67 days. Previously, Matthew Caufield worked at HC WAINWRIGHT.

Matthew Caufield’s has documented 234 price targets and ratings displayed on 20 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ADVM, Adverum Biotechnologies at 17-Nov-2025.

Wall Street Analyst Matthew Caufield

Analyst best performing recommendations are on HLVX (HILLEVAX).
The best stock recommendation documented was for MLYS (MINERALYS THERAPEUTICS, COMMON STOCK) at 8/13/2025. The price target of $42 was fulfilled within 58 days with a profit of $28.44 (209.73%) receiving and performance score of 36.16.

Average potential price target upside

ALDX Aldeyra The EYEN Eyenovia FDMT 4D Molecular Therapeutics  ISEE IVERIC bio OCUP Ocuphire Pharma OPT Opthea Ltd LYRA Lyra Therapeutics  UBX Unity Biotechnology GMTX Gemini Therapeutics ADVM Adverum Biotechnologies DMAC DiaMedica Therapeutics KOD Kodiak Sciences OPTN OptiNose PHAT Phathom Pharmaceuticals HLVX Hillevax LENZ LENZ Therapeutics MLYS Mineralys Therapeutics, Common Stock FBLG FibroBiologics, Common Stock SRZN Surrozen IMUX Immunic

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$10

$4.41 (78.89%)

7 months 8 days ago
(19-May-2025)

0/11 (0%)

$7.58 (313.22%)

Buy

$6

$0.41 (7.33%)

$24

8 months 23 days ago
(04-Apr-2025)

0/3 (0%)

$4.11 (217.46%)

Buy

$10

$4.41 (78.89%)

1 years 4 months 19 days ago
(08-Aug-2024)

0/1 (0%)

$5.81 (138.66%)

Buy

$8

$2.41 (43.11%)

$25

2 years 2 months 10 days ago
(17-Oct-2023)

0/10 (0%)

$6.16 (334.78%)

Hold

$14

2 years 2 months 10 days ago
(17-Oct-2023)

2/3 (66.67%)

$6.42 (84.70%)

362

Show more analysts

Please expand the browser size to see the chart

Which stock is Matthew Caufield is most bullish on?

Potential upside of $17.28 has been obtained for LENZ (LENZ THERAPEUTICS)

Which stock is Matthew Caufield is most reserved on?

Potential downside of $0.84 has been obtained for ADVM (ADVERUM BIOTECHNOLOGIES)

What Year was the first public recommendation made by Matthew Caufield?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?